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Synopsis 13 
Objectives 14 
To develop a Galleria mellonella infection model to assess the in vivo efficacy of phage therapy against 15 
laboratory and clinical strains of Pseudomonas aeruginosa. 16 
Methods 17 
Galleria were infected with P. aeruginosa PA01 and treated with varying multiplicity of infection of 18 
phage either two hours post-infection (treatment) or two hours pre-infection (prevention) via 19 
injection into the haemolymph. To address the kinetics of infection larvae were bled over a period of 20 
24 hours for quantification of bacteria and phage.  Finally, clinical strains from acute and chronic cystic 21 
fibrosis infections were used in the prevention model to further validate the model.   22 
Results 23 
Survival rates at 24 hours when infected with 10 cells/larvae were greater with the prevention model 24 
versus treatment model (47 vs 40% MOI 10, 47 vs 20 % MOI 1 and 33 vs 7% MOI 0.1).  This pattern 25 
also held true when infected with 100 cells/larvae (87% vs 20% MOI 10; 53% vs 13 % MOI 1; 67% vs 26 
7% MOI 0.1).  By 24 hours post infection phage had kept bacterial numbers in the haemolymph to 27 
1000-fold lower than the non-treated group.  Phage increased survival of Galleria when infected with 28 
both the acute (0% vs 85%) and chronic (80% vs 100%) clinical P. aeruginosa strains. 29 
Conclusions 30 
Here we present data for the use of G. mellonella as a simple, robust and cost-effective model for the 31 
initial in vivo examination P. aeruginosa targeted phage therapy which may be applied to other 32 
pathogens with similarly low infective doses. 33 
 34 
Introduction 35 
Multi-drug resistant bacterial pathogens pose an ever increasing threat to human health.  This 36 
problem is in part due to a lack of novel antibiotics approved for use over the last few decades resulting 37 
in an urgent need to identify new avenues for treating bacterial infections, especially those caused by 38 
gram-negative pathogens1 Pseudomonas aeruginosa is an opportunistic pathogen that is a leading 39 
cause of infection among burns victim and patients with cystic fibrosis. It is also responsible for a large 40 
number of health-care associated infections. To make matters worse, P. aeruginosa is associated with 41 
hypermutability and due to high antibiotic selective pressure has given rise to the emergence of multi-42 
drug resistant strains in the population and concerns about available effective treatments are 43 
growing.2, 3  In the UK resistance to two or more antibiotics among P. aeruginosa isolated from the 44 
lungs of cystic fibrosis (CF) patients has risen to 40%.4  This is a worrying statistic as colonisation of the 45 
CF lung with P. aeruginosa is a predictor of poor prognosis and associated with a 2-3 fold increased 46 
chance of death over an eight year period.5 For this reason novel anti-invectives are needed.  47 
 48 
Facing such a scenario interest in phage therapy in Western society has experienced resurgence after 49 
research into this area fell out of favour following the discovery of antibiotics.  Bacteriophages (or 50 
phages) are viral particles able to infect bacterial cells with high specificity, taking over cellular function 51 
to replicate its genome. Upon maturation is complete the bacterial cell wall is lysed to release viral 52 
progeny.  53 
Phage therapy can be broadly subdivided in to four main categories.6  (1) Conventional phage therapy 54 
principally uses lytic phage to lyse target bacterial species.   (2) Modified phage therapy utilizes 55 
genetically altered phage with favourable properties such as non-lytic replication to avoid the 56 
possibility of endotoxin shock, when bacterial cells are lysed. (3) Treatment with enzymes derived 57 
from phage such as administration of endolysins to selectively degrade the bacterial peptidoglycan 58 
cell wall. (4) Finally is the concept of combination therapy with phage and antibiotics where phage 59 
exhibit properties to degrade polysaccharide components of biofilms therefore allowing antibiotics to 60 
penetrate and elicit an action.7  61 
Although in vitro systems allow for a reductionist approach to examining phage interactions with 62 
target bacteria, it does not take into account a more complex in vivo system.  Mammalian models are 63 
an excellent means of testing phage therapy, but require ethical approval, significant infrastructure 64 
and funds.  The Galleria mellonella model fills the void between these two systems providing a cheap, 65 
reliable and ethics free system for testing novel antimicrobials.8  Here we describe the first use of the 66 
G. mellonella model to examine the treatment of P. aeruginosa infection with phage therapy.   67 
 68 
Materials and Methods 69 
Bacterial strains and preparation of inoculum 70 
Phage therapy was assessed using P. aeruginosa PAO1 and two clinical isolates, PA45291 and 71 
BC00907, isolated from cystic fibrosis patients with acute and chronic infections, respectively. Bacteria 72 
were grown to mid-log phase in LB and washed once in PBS.  Cells were resuspended in PBS to give a 73 
final cell number of 1x108 cfu ml-1 and diluted accordingly in PBS to give the required inoculum size for 74 
each experiment.   75 
 76 
Phage cocktail preparation and titration 77 
Six distinct phages infecting all the P. aeruginosa strains mentioned above were combined to establish 78 
a cocktail suspension. Phage solutions were propagated on PAO1. Briefly, 100 μl of phage lysate and 79 
100 μl of host growing culture were mixed and left for 5 min at room temperature. Following 80 
incubation, 3 ml of LB soft-agar containing 0.65% bacteriological agar was added and poured onto 81 
agar plates. After an overnight incubation at 37°C, plates displaying confluent lysis were selected and 82 
3 ml of SM buffer (5 M NaCl, 1M MgSO4, 1 M Tris–HCl [pH 7.5], 0.01% w/v gelatine) and 2% (vol/vol) 83 
chloroform were added before incubation at 37°C for 4h. High-titre phage solution was removed from 84 
the plates, centrifuged (8,000 x g, 10 min) to remove cell debris, and then filter sterilized (pore size, 85 
0.22 μm).  A PEG purification step was further added to remove any possible bacterial remainings from 86 
the suspensions and the final solutions were stored at 4oC. All the necessary dilutions were performed 87 
in SM buffer. For the titration of the bacteriophage content in the haemolymph, a similar methodology 88 
to the propagation was followed. The several dilutions were mixed with the host bacterial cells and 3 89 
ml of soft agar was added and poured onto agar plates. After an overnight incubation plaques were 90 
counted to determine phage titre. 91 
 92 
G. mellonella phage therapy assay 93 
Larvae of G. mellonella were obtained from Livefood UK Ltd (Somerset, UK). Larvae were stored at 4 94 
oC and used within 1 week of receipt. A modified methodology developed by Peleg was used to infect 95 
each Galleria, but in brief.8  Galleria were surface sterilized with a FASTAID pre-injection swab 96 
containing 70 % ethanol.  Using a pair of tweezers each Galleria was restrained and with a 26 gauge 97 
Terumo syringe 10 µl of inoculum containing either 100 or 10 cells of P. aeruginosa was delivered into 98 
the larval haemolymph behind the last proleg.  For the treatment model phage suspension was 99 
delivered behind the last proleg on the opposite side to the infection two hours post-infection and for 100 
the prevention experiment phage suspension was given two hours pre-infection. All experiments used 101 
15 larvae per treatment.  A positive control group, where the larvae were infected and treated with 102 
PBS solution, and two negative control groups were also included: one group injected with PBS only, 103 
assessing the impact of any negative effect from the injection process, and one group injected with 104 
phage suspension. Larvae were placed into petri dishes and incubated at 37 °C for 48 hours, being 105 
examined regularly and recorded as dead when they did not move in response to touch. 106 
 107 
Bleeding larvae haemolymph 108 
The prevention model was used to follow the kinetics of bacteria and phage interactions within the 109 
larval haemolymph over time.  The phage cocktail, or PBS, was administered two hours prior to 110 
infection with phage initially quantified within the haemolymph at time of infection (time zero).  111 
Galleria were infected with 100 cells of P. aeruginosa PA01 and at time points of eight and 24 hours 112 
three Galleria were sacrificed and bled following incision made with forceps to quantify phage and P. 113 
aeruginosa in both phage and PBS treated Galleria.  Titrations of haemolymph were made in SM buffer 114 
for phage counts and for PAO1 counts titrations were made in 10 mM of ferrous ammonium sulfate 115 
(FAS) (Sigma Aldrich, UK) for inactivation of extracellular phage prior to viable bacterial counts. 116 
Statistical analysis 117 
Kaplan-Meier survival curves were plotted using GraphPad Prism (GraphPad Software, Inc., La Jolla, 118 
CA, USA).  119 
 120 
Results 121 
Treatment of infection 122 
In this study two models of phage and infection interactions were examined.  The first was a treatment 123 
whereby Galleria were infected with either 10 or 100 cells of P. aeruginosa PA01 and left to allow an 124 
infection to establish for two hours.  Varying MOIs of phage were then administered and death was 125 
observed over 48 hours.  No death was seen in the PBS controls and Galleria which were treated with 126 
PBS died quicker when infected with 100 cells versus 10 cells.  Administration of phage prolonged the 127 
survival of the Galleria in a dose dependent manner, but 0% survival was eventually seen in all groups 128 
by 30 hours [Figure 1a].  At 24 hours there was 100% mortality in the infected and untreated Galleria, 129 
but 40% survival for those infected with 10 cells and treated with an MOI of 10 compared with 20% 130 
survival with those infected with 100 cells at the same MOI [Figure 1b].  131 
 132 
Prevention of infection 133 
The second model examined the effect of prevention of infection whereby Galleria were given a 134 
prophylactic dose of phage two hours prior to infection with P. aeruginosa PA01.  Similarly to the 135 
treatment experiment, Galleria infected with 100 cells died quicker than those infected with 10 cells 136 
when given PBS two hours before infection. [Figure 2a].  At 24 hours survival ranged from 80% in 137 
Galleria given an MOI of 100 to 35% in those given an MOI of 0.1 [Figre 2b].  Compared with 10 cells 138 
there was greater survival at 24 hours for all comparable MOIs when infection was established with 139 
100 cells.  Survival ranged from 90% to 60% in Galleria given MOIs of 100 and 1, respectively.  140 
 141 
Kinetics of P. aeruginosa infection and effect of phage treatment 142 
To understand the kinetics of a Pseudomonas infection within Galleria, larvae were infected with 100 143 
cells using the prevention model of infection.  Bacteria and phage were quantified at set time points 144 
by bleeding the haemolymph.  No endogenous Pseudomonas or phage with lytic activity against P. 145 
aeruginosa PA01 were detected in the uninfected controls. For the Galleria which were given P. 146 
aeruginosa PA01 only the numbers of cells isolated from the heamolymph increased over the duration 147 
of the experiment.  By 24 hours all Galleria were dead and numbers of P. aeruginosa were in the order 148 
of 108 c.f.u/ml.  The second group of Galleria were given a prophylactic dose of phage 2 hours prior to 149 
infection and phage and bacteria were then quantified over the course of infection.  Numbers of P. 150 
aeruginosa PA01 were comparable to that of the non-treated Galleria after 8 hours infection, but were 151 
three orders of magnitude less cells at 24 hours compared with the non-treated Galleria.  These 152 
Galleria were alive at 24 hours.  Numbers of phage increased over the duration of the infection 153 
reaching a peak titre at 24 hours of 108 p.f.u/ml. 154 
 155 
Clinical isolates of P. aeruginosa 156 
To validate the model of phage therapy with P. aeruginosa we sought to test the model with clinical 157 
strains isolated from cystic fibrosis patients experiencing acute and chronic episodes of P. aeruginosa 158 
infections. With the PA45291 acute strain all infected Galleria were dead by 24 hours whereas there 159 
was 60 % survival at 28 hours in the group which were treated with phage at an MOI 10.  When Galleria 160 
were infected with the BC09007 chronic strain there was little death at 24 hours (90%) when given 161 
PBS as treatment, but 100 % survival in the phage treated group.  By 40 hours all Galleria were then 162 
dead.  163 
Discussion 164 
To avoid a scenario whereby society is plunged back into a pre-antibiotic era we need to urgently 165 
identify novel anti-bacterial agents.  Phage therapy offers a novel non-antibiotic approach to help in 166 
this battle.  The benefits of phage therapy include no cross resistance from pre-existing antibiotic 167 
resistant organisms, high selectivity therefore not wiping out the host microbiota unlike antibiotics as 168 
well as being deemed as safe in trials.9-11 169 
The G. mellonella infection model provides a system that can bridge the gap between in vitro studies 170 
and more advanced mammalian studies giving initial proof of principle data.  Mammalian models are 171 
crucial for testing the efficacy of phage prior to human trials, but drawbacks include the need for 172 
sufficient infrastructure, substantial costs,  as well as the need for ethical approval.  Galleria larvae 173 
have been used to examine numerous host-pathogen interactions ranging from studies of 174 
pathogenicity to antimicrobial activity with a small number of these examining the potential for phage 175 
therapy.12-14 176 
 177 
The strain of P. aeruginosa PA01 proved to be highly virulent with only 10 cells per Galleria required 178 
to result in death at 24 hours.  This is a very low infective dose in this model with organism such as S. 179 
aureus requiring 105 -106 cells/Galleria for death, A. baumannii requires greater than 104 and for 180 
Helicobacter pylori 106-107 cells are required for establishment of infection.15-17 This low infectious 181 
dose is of particular interest as it reduces the chances of endotoxin shock due to rapid lysis of high 182 
numbers of Gram negative cells. 183 
Two models of therapy were examined.  The first was a treatment methodology whereby an acute 2 184 
hour infection was allowed to establish prior to administration of phage.    At all MOIs of phage there 185 
was prolonged survival of the Galleria regardless whether 10 or 100 bacterial cells were used as the 186 
inoculum.  Although there was increased survival compared with the control there was a difference in 187 
survival depending on the number of cells in the inoculum.  Presumably the 10-fold higher inoculum 188 
of 100 cells vs 10 cells had meant that the infection had become more established within the two hour 189 
time frame therefore reducing the efficacy of the phage to prolong survival. 190 
The second model examined the ability to prevent infection using a prophylactic administration of 191 
phage two hours prior to infection.  When compared with the treatment model, prophylactic 192 
administration of phage resulted in greater survival after 24 hours at all comparable MOI values.  193 
Presumably this increased efficacy was the result of phage being able to distribute throughout the 194 
haemolymph over the two hour period prior to infection, where as in the treatment model the 195 
bacteria will have had opportunity to establish and begin to express toxins.  Interesting was the 196 
observation of greater survival among Galleria which received the higher inoculum of 100 cells, 197 
compared with 10 cells.  This may have been due to the higher number of bacterial cells resulting in 198 
an increased chance of bacteria and phage interaction resulting in a more rapid amplification of the 199 
phage. 200 
In both models phage treated Galleria eventually succumbed to the infection resulting in death by 30 201 
hours post infection.  For this reason we explored the kinetics of both the P. aeruginosa infection as 202 
well as effect phage had on bacterial numbers in vivo.  The most striking observation was the 203 
comparison between numbers of P. aeruginosa in the phage treated and untreated Galleria.  At 24 204 
hours the phage had kept the number of P. aeruginosa to 1000-fold less than the non-treated Galleria, 205 
but even in the presence of high titres of phage there had still been active growth, and therefore 206 
infection, from the P. aeruginosa over the duration of the experiment.  We had previously 207 
hypothesised that the reason for eventual death was the lack of available phage for clearance.  From 208 
Figure 3 it is clear that this is not the case due to the high titre of phage within the haemolymph, 209 
although the MOI had shifted from 100 to less than 1 by 24 hours.  This hypothesis was also ruled out 210 
by an experiment where Galleria were given a second dose of phage four hours after an initial dosing, 211 
but there was no difference when compared with the single dose control (data not shown).  One 212 
possibility for the continual survival of PA01 in the presence of a high titre of phage was the evolution 213 
of phage resistance within the Galleria.  This was ruled out after observation of no bacterial growth 214 
when co-cultivating P. aeruginosa single colonies, recovered at 24 hours after phage treatment, and 215 
a suspension of phage cocktail (data not shown).  The final explanation for the survival would be the 216 
intracellular localisation of Pseudomonas.  In these experiments we only examined bacterial numbers 217 
within extracted haemolymph.  Pseudomonas aeruginosa is known to have the ability to invade 218 
epithelial cells which would protect from attack from the phage.18   This highlights one of the 219 
limitations of phage therapy on pathogens which are able to exist and replicate in an intracellular 220 
environment.  Perhaps combination therapy with antibiotics which can enter host cells such as a 221 
fluoroquinolone or tetracycline would have aided in clearance, but this was beyond the scope of this 222 
study.  This potential intracellular survival strategy would also explain why the prevention model 223 
showed improved survival compared with the treatment model where the P. aeruginosa will have had 224 
time to establish within cells before the Galleria received a dose of the phage.  Although we 225 
hypothesise the lack of P. aeruginosa clearance was due to intracellular localisation, there must have 226 
been a degree of extracellular replication of cells within the haemolymph to allow for the observed 227 
propagation of the phage over time. 228 
Finally we looked to demonstrate the effectiveness of the phage model on clinical isolates of P. 229 
aeruginosa.  To do this the prevention model was repeated with clinical isolates from an acute and a 230 
chronic CF infection.  Here,  the acute isolate resulted in rapid death of the Galleria within 24 hours, 231 
with 85 % survival when given phage at an MOI of 10.  Interestingly the chronic isolate was less virulent 232 
at 24 hours compared with the acute and PA01 strains, but 100 % mortality was then seen by 40 hours.  233 
In conclusion we present data for the use of the G. mellonella as a simple, robust and cost-effective 234 
model for initial examination P. aeruginosa targeted phage therapy.  235 
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  290 
Figure legends 291 
Figure 1. Kaplan-Meier survival curves of G. mellonella infected with (A) 100 cells or (B) 10 cells of P. 292 
aeruginosa PA01 and treated with phage at varying multiplicities of infection two hours post-infection. 293 
C. Percentage of G. mellonella survival at 24 hours. 294 
 295 
Figure 2. Kaplan-Meier survival curves of G. mellonella infected with (A) 100 cells or (B) 10 cells of P. 296 
aeruginosa PA01 and pre-treated with phage at varying multiplicities of infection two hours pre-297 
infection. C. Percentage of G. mellonella survival at 24 hours. 298 
 299 
Figure 3. In vivo kinetics of P. aeruginosa infection within G. mellonella with and without phage 300 
treatment.  301 
 302 
Figure 4. Kaplan-Meier survival curves of G. mellonella infected with 10 cells of (A) acute P. aeruginosa 303 
PA45291 or (B) chronic P. aeruginosa BC09007 and pre-treated with phage at an MOI 10 two hours 304 
pre-infection.  305 
 306 
